Huang B, Lin B, Zheng H, Zheng B, Xue X, Liu M
    
    
    Mol Divers. 2025; .
  
  
    PMID: 39888540
    
    
          DOI: 10.1007/s11030-025-11115-8.
      
 
                                  
  
    Freire N, Herlinger A, Vanini J, Dalmolin M, Fernandes M, Nor C
    
    
    Cells. 2025; 14(2).
  
  
    PMID: 39851500
    
          PMC: 11763699.
    
          DOI: 10.3390/cells14020072.
      
 
                                  
  
    Mella C, Tsarouhas P, Brockwell M, Ball H
    
    
    Cancers (Basel). 2025; 17(1.
  
  
    PMID: 39796780
    
          PMC: 11719864.
    
          DOI: 10.3390/cancers17010154.
      
 
                                  
  
    Bieuville M, Dujon A, Raven N, Ujvari B, Pujol P, Eslami-S Z
    
    
    Evol Appl. 2024; 17(10):e70024.
  
  
    PMID: 39444444
    
          PMC: 11496201.
    
          DOI: 10.1111/eva.70024.
      
 
                                  
  
    Freire N, Herlinger A, Vanini J, Dalmolin M, Fernandes M, Nor C
    
    
    bioRxiv. 2024; .
  
  
    PMID: 39386542
    
          PMC: 11463451.
    
          DOI: 10.1101/2024.09.23.614476.
      
 
                              
              
                              
                                      
  Functional gene signature offers a powerful tool for characterizing clinicopathological features and depicting tumor immune microenvironment of colorectal cancer.
  
    Zhu Z, Li J, Fa Z, Xu X, Wang Y, Zhou J
    
    
    BMC Cancer. 2024; 24(1):1199.
  
  
    PMID: 39342165
    
          PMC: 11437988.
    
          DOI: 10.1186/s12885-024-12996-y.
      
 
                                          
                                                          
  Unveiling the potential of phytochemicals to inhibit nuclear receptor binding SET domain protein 2 for cancer: Pharmacophore screening, molecular docking, ADME properties, and molecular dynamics simulation investigations.
  
    Mohamed G, Abdallah H, Sindi I, Ibrahim S, Alzain A
    
    
    PLoS One. 2024; 19(8):e0308913.
  
  
    PMID: 39163297
    
          PMC: 11335128.
    
          DOI: 10.1371/journal.pone.0308913.
      
 
                                          
                                                          
  Pediatric Tumors as Disorders of Development: The Case for In Vitro Modeling Based on Human Stem Cells.
  
    Clairmont C, Gell J, Lau C
    
    
    Cancer Control. 2024; 31:10732748241270564.
  
  
    PMID: 39118322
    
          PMC: 11311176.
    
          DOI: 10.1177/10732748241270564.
      
 
                                          
                                                          
  Targeting DNA Methylation Machinery in Pediatric Solid Tumors.
  
    Cristalli C, Scotlandi K
    
    
    Cells. 2024; 13(14.
  
  
    PMID: 39056791
    
          PMC: 11275080.
    
          DOI: 10.3390/cells13141209.
      
 
                                          
                                                          
  Single-cell multiomics reveals ENL mutation perturbs kidney developmental trajectory by rewiring gene regulatory landscape.
  
    Song L, Li Q, Xia L, Sahay A, Qiu Q, Li Y
    
    
    Nat Commun. 2024; 15(1):5937.
  
  
    PMID: 39009564
    
          PMC: 11250843.
    
          DOI: 10.1038/s41467-024-50171-w.
      
 
                                          
                                                          
  Genomic Newborn Screening for Pediatric Cancer Predisposition Syndromes: A Holistic Approach.
  
    Linga B, Mohammed S, Farrell T, Rifai H, Al-Dewik N, Qoronfleh M
    
    
    Cancers (Basel). 2024; 16(11).
  
  
    PMID: 38893137
    
          PMC: 11171256.
    
          DOI: 10.3390/cancers16112017.
      
 
                                          
                                                          
  Clinical and molecular characteristics of Korean patients with Kabuki syndrome.
  
    Yoon J, Hwang S, Bae H, Kim D, Seo G, Koh J
    
    
    J Hum Genet. 2024; 69(9):417-423.
  
  
    PMID: 38824232
    
    
          DOI: 10.1038/s10038-024-01258-1.
      
 
                                          
                                                          
  Developmental origins shape the paediatric cancer genome.
  
    Chen X, Yang W, Roberts C, Zhang J
    
    
    Nat Rev Cancer. 2024; 24(6):382-398.
  
  
    PMID: 38698126
    
          PMC: 11571274.
    
          DOI: 10.1038/s41568-024-00684-9.
      
 
                                          
                                                          
  Associations in cell type-specific hydroxymethylation and transcriptional alterations of pediatric central nervous system tumors.
  
    Lee M, Azizgolshani N, Zhang Z, Perreard L, Kolling F, Nguyen L
    
    
    Nat Commun. 2024; 15(1):3635.
  
  
    PMID: 38688903
    
          PMC: 11061294.
    
          DOI: 10.1038/s41467-024-47943-9.
      
 
                                          
                                                          
  Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia.
  
    Ou J, Deng S, Ding C, Cai Z, Chen J, Huang Z
    
    
    Ann Hematol. 2024; 103(9):3639-3648.
  
  
    PMID: 38451293
    
    
          DOI: 10.1007/s00277-024-05681-4.
      
 
                                          
                                                          
  Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
  
    Cevatemre B, Bulut I, Dedeoglu B, Isiklar A, Syed H, Bayram O
    
    
    Cell Death Dis. 2024; 15(2):132.
  
  
    PMID: 38346967
    
          PMC: 10861560.
    
          DOI: 10.1038/s41419-024-06422-1.
      
 
                                          
                                                          
  Identification of a de novo variant in the ASXL2 gene related to Shashi-Pena syndrome.
  
    Zheng Y, Yang L, Niu M, Zhao S, Liang L, Wu Y
    
    
    Mol Genet Genomic Med. 2023; 11(11):e2251.
  
  
    PMID: 37493007
    
          PMC: 10655504.
    
          DOI: 10.1002/mgg3.2251.
      
 
                                          
                                                          
  The role of chromatin remodeler SMARCA4/BRG1 in brain cancers: a potential therapeutic target.
  
    Navickas S, Giles K, Brettingham-Moore K, Taberlay P
    
    
    Oncogene. 2023; 42(31):2363-2373.
  
  
    PMID: 37433987
    
          PMC: 10374441.
    
          DOI: 10.1038/s41388-023-02773-9.
      
 
                                          
                                                          
  SETD2-H3K36ME3: an important bridge between the environment and tumors.
  
    He J, Xu T, Zhao F, Guo J, Hu Q
    
    
    Front Genet. 2023; 14:1204463.
  
  
    PMID: 37359376
    
          PMC: 10288198.
    
          DOI: 10.3389/fgene.2023.1204463.
      
 
                                          
                                                          
  Effects of post-transplant maintenance therapy with decitabine prophylaxis on the relapse for acute lymphoblastic leukemia.
  
    Fan J, Lu R, Zhu J, Guo X, Wan D, Xie X
    
    
    Bone Marrow Transplant. 2023; 58(6):687-695.
  
  
    PMID: 36964223
    
    
          DOI: 10.1038/s41409-023-01948-y.